Accessibility Menu
Xvivo Perfusion Ab (publ) logo

Xvivo Perfusion Ab (publ)(OTC) XVIPF

Market Cap$974.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)+423%
5 Year-32%
1 Year+51%
1 Month+19%
$30.95
+0.00%
+0.00Today
Xvivo Perfusion Ab (publ) last closing stock price
MetricPriceDate
Last closeUSD 30.952026-08-17
Xvivo Perfusion Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.17%USD 30.002026-08-10
1 month+18.72%USD 26.072026-07-16
3 month+5.31%USD 29.392026-05-19
Year to date+49.52%USD 20.702025-12-30
1 year+50.71%USD 20.542025-08-13
3 year+10.73%USD 27.952023-08-08
5 year-31.83%USD 45.402021-08-13
Since inception+422.8%USD 5.922014-07-23

Xvivo Perfusion Ab (publ) Financials at a Glance

Market Cap

$974.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 891.31M

Net Income (TTM)

SEK 88.32M

EPS (TTM)

$0.30

P/E Ratio

102.28

Dividend

$0.00

Beta (Volatility)

0.28 (Low)

Price

$30.95

Volume

100

Open

$30.95

Previous Close

$30.95

Daily Range

$30.95 - $30.95

52-Week Range

$16.98 - $30.95

Estimated Earnings Date

Oct 22, 2026

XVIPF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Xvivo Perfusion Ab (publ)

Xvivo Perfusion AB (publ) is a medical technology company focused on advancing transplantation medicine. The firm specializes in innovative solutions for the preservation and perfusion of organs, tissues, and cells, which are critical for successful transplant procedures.

Products and Services
  • XVIVO System (XPS) for normothermic ex vivo lung perfusion
  • XPS Disposable Lung Kit for essential EVLP components
  • STEEN Solution, a buffered extracellular fluid for lung perfusion
Growth Outlook
  • Significant international presence across multiple markets
  • Continued investment in research and development to enhance product offerings
  • Increasing demand for organ transplantation solutions globally
Financial Highlights
  • Q2 2026 revenue of 236.9 million SEK, showing strong market performance
  • Net income of 16.1 million SEK in Q2 2026, reflecting operational efficiency
  • TTM gross profit margin of 62.8%, indicating robust profitability
Xvivo Perfusion AB (publ) has established itself as a leader in the medical devices sector, particularly in transplantation medicine. The company's innovative products, such as the XVIVO System and STEEN Solution, are designed to improve the success rates of organ transplants, addressing a critical need in healthcare. With a strong focus on research and development, Xvivo is well-positioned to capitalize on the growing demand for organ transplantation solutions worldwide. Recent financial performance highlights, including a notable revenue increase and solid net income, underscore the company's operational efficiency and market strength. The impressive gross profit margin further indicates a sustainable business model, making Xvivo an intriguing option for potential investors interested in the healthcare sector.
AI Generated • Aug 8, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

197

CEO

Christoffer Rosenblad, MBA

Website

www.xvivogroup.com

Headquarters

Mölndal, VG SE-431 53, SE

XVIPF Financials

Key Financial Metrics (TTM)

Gross Margin

62.85%

Operating Margin

12.66%

Net Income Margin

9.89%

Return on Equity

4.13%

Return on Capital

4.16%

Return on Assets

3.51%

Earnings Yield

0.98%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$974.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

31.50M

Volume

100

Avg. Volume

60.175

Financials (TTM)

Gross Profit

SEK 591.91M

Operating Income

SEK 109.00M

EBITDA

SEK 183.38M

Operating Cash Flow

SEK 235.45M

Capital Expenditure

-SEK 180.06M

Free Cash Flow

SEK 141.87M

Cash & ST Invst.

SEK 31.32M

Total Debt

SEK 12.49M

Xvivo Perfusion Ab (publ) Performance Analysis

Xvivo Perfusion Ab (publ) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 41,037,19136.3%
20232023-12-31SEK 56,287,22237.2%
20242024-12-31SEK 77,786,43138.2%
20252025-12-31SEK 82,810,5296.5%
Xvivo Perfusion Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-305.4%
Q42025-12-3120.1%
Q12026-03-316.8%
Q22026-06-30-1.7%
Xvivo Perfusion Ab (publ) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK 0.0688.1%
20232023-12-31SEK 0.29368.2%
20242024-12-31SEK 0.5178.1%
20252025-12-31SEK 0.08-84.2%
Xvivo Perfusion Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30180.0%
Q42025-12-31614.3%
Q12026-03-3115.0%
Q22026-06-30-55.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

SEK 236.94M

+32.9%

Gross Profit

SEK 149.83M

+12.9%

Gross Margin

63.23%

N/A

Market Cap

$974.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.64M

N/A

Employees

210

N/A

Net Income

SEK 16.14M

+926.2%

EBITDA

SEK 41.63M

+487.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

SEK 31.32M

-90.3%

Total Debt

SEK 12.49M

+7.1%

Accounts Receivable

SEK 20.13M

-88.9%

Inventory

SEK 23.40M

-91.3%

Long Term Debt

SEK 11.29M

-89.0%

Short Term Debt

SEK 1.20M

+46.0%

Return on Assets

3.51%

N/A

Return on Invested Capital

4.85%

N/A

Free Cash Flow

SEK 0.00

-100.0%

Operating Cash Flow

SEK 62.95M

+615.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AVNBFAvon Technologies Plc
$22.49+0.00%
SOLTFNxera Pharma Co., Ltd.
$5.01+0.00%
CALZFPolynovo Limited
$0.62+0.00%
VBIZFViva Biotech Holdings
$0.17+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.48-0.02%
INTCIntel
$96.69-0.07%
NOKNokia
$10.39-0.04%
NVDANvidia
$219.74-0.02%

Questions About XVIPF

What is the current price of Xvivo Perfusion Ab (publ)?

Xvivo Perfusion Ab (publ) is trading at $30.95 per share.

What is the 52-week range for Xvivo Perfusion Ab (publ)?

Over the past 52 weeks, Xvivo Perfusion Ab (publ) has traded between $16.98 and $30.95.

How much debt does Xvivo Perfusion Ab (publ) have?

As of the most recent reporting period, Xvivo Perfusion Ab (publ) reported total debt of SEK 12.57M.

How much cash does Xvivo Perfusion Ab (publ) have on hand?

Xvivo Perfusion Ab (publ) reported SEK 31.51M in cash and cash equivalents in its most recent financial results.

What is Xvivo Perfusion Ab (publ)’s dividend yield?

Xvivo Perfusion Ab (publ) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services